Tresiba is the new once-daily basal insulin with an ultra-long duration of action for the treatment of type 1 and type 2 diabetes.
Tresiba successfully achieved equivalent reductions in HbA1c and was associated with significantly lower risk of night-time hypoglycaemia in the treat-to-target studies.
Tresiba will be made available in Novo Nordisk’s latest prefilled insulin pen with an easy push-button FlexTouch and in Penfill, designed for used with Novo Nordisk’s insulin delivery systems.